Sun Pharma Q2 Results: Profit Increases 28%, Meets Estimates
Sun Pharmaceuticals Ltd.'s consolidated net profit rose in the second quarter of the current financial year, meeting analysts' estimates.
The drugmaker's profit rose 27.94% to Rs 3,040 crore in the quarter-ended Sept. 30, 2024, according to an exchange filing on Monday. That compares with the Rs 2,932-crore consensus estimate of analysts tracked by Bloomberg.
Sun Pharmaceuticals Industries Q2 FY25 Highlights (Consolidated, YoY)
Revenue up 9.01% to Rs 13,291.4 crore (Bloomberg estimate: Rs 13,321 crore).
Ebitda up 32.2% to Rs 3,939 crore (Estimate: Rs 3,753 crore).
Margin at 29.63% versus 24.43% (Estimate: 28.2%).
Net profit up 27.94% to Rs 3,040 crore (Estimate: Rs 2,932 crore).
The company's other income grew 17.5% at Rs 354 crore versus Rs 293 crore. The research and development expenses were slightly lower than expected at 6% of sales. They were expected to be at 6.9% of sales. Net profit increased on the back of lower research and development expenses and US business growth.
Key Earnings Highlights
US Formulations sales were at $517 million for Q2 FY25, growing by 20.3% over the same period last year and accounting for approximately 33% of total consolidated sales. For the first half, sales were at $983 million, growing by 9.1% over same period last year.
Formulation sales in emerging markets were at $293 million for Q2 FY25, growing by 3.2% over Q2 last year and accounting for approximately 18% of total consolidated sales. For the first half, sales were at $577 million, growing by 5.9% over same period last year.
Formulation sales in Rest of World markets, excluding India, US and Emerging Markets, were $199 million in Q2 FY25, declining by 3.5% vs Q2 last year and accounting for approximately 13% of total consolidated sales. For the first half, sales were at $388 million, declining by 3.2% over same period last year.
External sales of API were Rs 533 crore in Q2 FY25, growing by 7.4% over Q2 last year. For the first half, API sales were at Rs 1,028 crore, declining slightly over first half last year.
API business imparts benefits of vertical integration and continuity of supply chain for our formulations business.
Consolidated R&D investment were Rs 792 crore for Q2 FY25, or 6% of sales as compared to Rs 773 crore for Q2 last year.
Shares of Sun Pharmaceuticals Industries were trading 2.7% higher at Rs 1910.64 apiece on the NSE, as compared to a 0.9% advance in the benchmark NSE Nifty 50.
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
